Setting Expectations With Trial Outcomes

Patients facing second-line therapy for metastatic pancreatic cancer most often want to know how long they will live. Anne Noonan, MB BCh, PhD, leads with the significant overall survival benefit of daraxonrasib over second-line chemotherapy in the RASolute 302 trial, then discusses response rate, since patients watch their scans closely, and then quality of life. Jonathan Lee, MD, notes that many patients arrive with information and opinions, including from artificial intelligence tools, so he first aligns with them emotionally. He describes the emotional swing of learning about progression and then about an oral option with superior outcomes, and he emphasizes the improved quality of life reported with daraxonrasib vs chemotherapy. Paul E. Oberstein, MD, cautions that the therapy is not a cure and carries its own side effects. He contrasts trial participants, who accept unknowns, with real-world patients who need detailed preparation. According to Dr. Oberstein, some patients choose not to start or delay starting; most find the data appealing.